REGN: Rounding Bottom detected on 4 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 47 setups from the 4 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 4 Nov 2026, our scan flagged REGN as a rounding bottom setup scoring 74 out of 98 (Good tier), with a 70% win probability based on our historical pattern database and a 1.04 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $973.36, the conservative target is $1020.45 with a stop at $928.03.

74 of 98
Good
70%
High
1.04 : 1
$47.09 to target $45.33 to stop
Swing Trading Plan
Entry
$973.36
$1020.45
$928.03
2-8 trading days
+$14.99
Exp. Reward
+$26.15
Exp. Risk
-$11.16

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
REGN is forming a rounding bottom pattern with exceptional structural quality (15.0/15). The stock trades at $973.36, having recovered 64.74% from its 52-week low with key resistance at $789.15 and critical support at $590.83. Volume participation is elevated at 1.46x average (1.19M shares), though breakout volume scores at 10.0 suggest the move requires confirmation. The overall pattern quality registers 74.15 with 70.3% win probability, supported by strong MACD momentum (+17.73). The three-white-soldiers confirmation formed Oct 30th—the exact day Q3 earnings drove a 26.3% single-day surge.
Stock Context
Regeneron reported Q3 2026 revenues increased 36% to $5.1 billion versus Q3 2025, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales. On October 31, 2026, Regeneron led healthcare sector gains with a 26.3% stock price increase following robust third-quarter earnings. An expanded collaboration with Sanofi added $1.0 billion up-front to be recognized as collaboration revenue in Q4 2026 with potential to receive up to an additional $7.0 billion in future milestones. Regeneron price targets were raised to $913 from $810 at RBC Capital and to $997 from $835 at Leerink on November 2, 2026. The rounding bottom inflection aligns precisely with this earnings-driven momentum and analyst upgrade cycle.
What to Expect
A successful breakout above $789.15 resistance would target the conservative measured move of $1,020.45 (4.8% upside from current price). Volume confirmation is critical—breakout volume must exceed the current 1.46x ratio to sustain the move. The 70.3% win probability reflects strong historical precedent for this pattern type. Invalidation occurs decisively below $590.83, which represents 39.3% downside risk. The pattern requires sustained volume and price discipline above $789.15 to confirm the breakout is legitimate and not a head-fake in a still-elevated RSI environment (82.74).
Risk Factors
RSI at 82.74 signals overbought conditions—a critical vulnerability after a 33.98% one-month surge. Regeneron plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and initiate a Phase 3 study in MASH/MASLD in Q4 2026, creating near-term event risk. The negative beta (-0.22) suggests REGN will move inverse to broader market if equity markets correct—problematic in the current bearish regime (-0.31). A 20-day volatility of 50.85% combined with elevated ATR ($28.98) indicates sharp reversals are probable. Sector remains bullish (+0.93), but macro headwinds could force quick profit-taking after October's outsized gains. Any disappointment on pipeline trials or Sanofi collaboration progress could trigger sharp volatility.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is REGN a good swing trade?
REGN scored 74 out of 98 on our rounding bottom scan, with a 70% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $973.36, with a conservative target of $1020.45 and a stop loss at $928.03.
What would invalidate this rounding bottom setup?
A close below the stop loss at $928.03 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical rounding bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.31
-1.0 0 +1.0
Health Care Sector
Bullish 0.93
-1.0 0 +1.0
Other Patterns Detected Today
Three White Soldiers
3 days in pattern
Weak 25.4
Overall Score
35 of 40
Strong
Pattern Quality
16 of 20
Strong
Setup
13 of 20
Moderate
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
10 of 13
Good
Breakout
10 of 12
Strong
Volume
Recent Performance
+19.3%
1W
+20.5%
2W
+34.0%
1M
+26.8%
3M
Momentum & Trend
RSI (14)
82.7
Overbought
MACD Histogram
+17.73
Strong Bullish
Bollinger Band Position
110.2%
Upper Band
Volatility & Risk
20-Day Volatility
0.51
Very High
ATR %
3.0%
Medium
Beta
-0.22
Defensive
Volume Analysis
Volume Ratio
1.46x
Above Avg
20-Day Avg Vol
823K
shares / day
Current Volume
1.2M
shares traded
Price Levels
Target
$1020.45
52W High
$975.51
Current
$973.36
Stop Loss
$928.03
Resistance
$789.15
52W Low
$590.85
Support
$590.83
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.